Adding four months of androgen deprivation therapy (ADT) to radiation treatment extends survival and delays metastasis in men with unfavorable intermediate-risk prostate cancer, according to a secondary analysis of a Phase 3 clinical trial. However, that new trial analysis showed there were no such benefits to ADT therapy for men with favorable intermediate-risk prostate cancer undergoing radiation therapy. These findings support the National Comprehensive Cancer Network recommendations that ADT treatment only be given to patients with…
You must be logged in to read/download the full post.
The post ADT Not Needed With Radiation in Favorable Intermediate-Risk PC appeared first on BioNewsFeeds.